NAD(P)H: Quinone oxidoreductase-1 overexpression predicts poor prognosis in small cell lung cancer

Oncology Reports

Volumn 32, Issue 6, 2014, Pages 2589-2595

  Cui, Xuelian ^a   Jin, Tiefeng ^a   Wang, Xiaoyan ^a   Jin, Guang ^a   Li, Zhuhu ^a   Lin, Lijuan ^a,b  

^a YANBIAN UNIVERSITY   (China)

^b EASTERN LIAONING UNIVERSITY   (China)

Author keywords

NAD(P)H:quinone oxidoreductase 1; Prognosis; Small cell lung cancer; Survival analysis

Indexed keywords

MESSENGER RNA; OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE) 1; UNCLASSIFIED DRUG; NQO1 PROTEIN, HUMAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; LUNG SURGERY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROTEIN EXPRESSION; PROTEIN FUNCTION; SMALL CELL LUNG CANCER; SURVIVAL RATE; TUMOR VOLUME; ENZYMOLOGY; GENE EXPRESSION; GENETICS; KAPLAN MEIER METHOD; LUNG; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SECONDARY;

ADULT; AGED; FEMALE; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NAD(P)H DEHYDROGENASE (QUINONE); PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SMALL CELL LUNG CARCINOMA;

EID: 84914668292     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3494     Document Type: Article

References (28)

1. Kallianos A, Rapti A, Zarogoulidis P, et al: Therapeutic procedure in small cell lung cancer. J Thorac Dis 5 (Suppl 4): S420-S424, 2013.
2. Rudin CM, Hann CL, Peacock CD and Watkins DN: Novel systemic therapies for small cell lung cancer. J Natl Compr Cancer Netw 6: 315-322, 2008.
3. Zhang Y and He J: The development of targeted therapy in small cell lung cancer. J Thorac Dis 5: 538-548, 2013.
4. Siegel D and Ross D: Immunodetection of NAD(P)H:quinine oxidoreductase 1 (NQO1) in human tissues. Free Radic Biol Med 29: 246-253, 2000.
5. Siegel D, Yan C and Ross D: NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. Biochem Pharmacol 83: 1033-1040, 2012.
6. Zhu CL, Huang Q, Liu CH, et al: NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T gene polymorphism association with digestive tract cancer: a meta-analysis. Asian Pac J Cancer Prev 14 2349-2354, 2013.
7. Buranrat B, Prawan A, Kukongviriyapan U, et al: Dicoumarol enhances gemcitabine-induced cytotoxicity in high NQO1-expressing cholangiocarcinoma cells. World J Gastroenterol 16: 2362-2370, 2010.
8. Lyn-Cook BD, Yan-Sanders Y, Moore S, et al: Increased levels of NAD(P)H: quinine oxidoreductase 1 (NQO1) in pancreatic tissues from smokers and pancreatic adenocarcinomas: a potential biomarker of early damage in the pancreas. Cell Biol Toxicol 22: 73-80, 2006.
9. Cheng Y, Li J, Martinka M and Li G: The expression of NAD(P)H:quinone oxidoreductase 1 is increased along with NF-κB p105/p50 in human cutaneous melanomas. Oncol Rep 23: 973-979, 2010.
10. Awadallah NS, Dehn D, Shah RJ, et al: NQO1 expression in pancreatic cancer and its potential use as a biomarker. Appl Immunohistochem Mol Morphol 16: 24-31, 2008.
11. Garate M, Wani AA and Li G: The NAD(P)H:quinone oxido-reductase 1 induces cell cycle progression and proliferation of melanoma cells. Free Radic Biol Med 48: 1601-1609, 2010.
12. Liu S, Li L, Zhang Y, et al: The oncoprotein HBXIP uses two pathways to up-regulate S100A4 in promotion of growth and migration of breast cancer cells. J Biol Chem 287: 30228-30239, 2012.
13. Kong J, Li Y, Liu S, et al: High expression of ezrin predicts poor prognosis in uterine cervical cancer. BMC Cancer 13: e520, 2013.
14. Lin L, Piao J, Gao W, et al: DEK over expression as an independent biomarker for poor prognosis in colorectal cancer. BMC Cancer 13: e366, 2013.
15. Lajin B and Alachkar A: The NQO1 polymorphism C609T (Pro187Ser) and cancer susceptibility: a comprehensive meta-analysis. Br J Cancer 109: 1325-1337, 2013.
16. Talalay P and Dinkova-Kostova AT: Role of nicotinamide quinine oxidoreductase 1 (NQO1) in protection against toxicity of electrophiles and reactive oxygen intermediates. Methods Enzymol 382: 355-364, 2004.
17. Lee J, Kim KS, Lee MH, et al: NAD(P)H: quinone oxidoreductase 1 and NRH:quinone oxidoreductase 2 polymorphisms in papillary thyroid microcarcinoma: correlation with phenotype. Yonsei Med J 54: 1158-1167, 2013.
18. Nair S, Xu C, Shen G, et al: Pharmacogenomics of phenolic anti-oxidant butylated hydroxyanisole (BHA) in the small intestine and liver of Nrf2 knockout and C57L/6J mice. Pharm Res 23: 2621-2637, 2006.
19. Kuehl BL, Paterson JW, Peacock JW, et al: Presence of a heterozygous substitution and its relationship to DT-diaphorase activity. Br J Cancer 72: 555-561, 1995.
20. Schulz WA, Krummeck A, Rösinger I, et al: Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics 7: 235-239, 1997.
21. Nagata M, Kimura T, Suzumura T, et al: C609T polymorphism of NADPH quinone oxidoreductase 1 correlates clinical hematological toxicities in lung cancer patients treated with amrubicin. Clin Med Insights Oncol 7: 31-39, 2013.
22. Malik MA, Zargar SA and Mittal B: Role of NQO1 609C>T and NQO2-3423G>A gene polymorphisms in esophageal cancer risk in Kashmir valley and meta analysis. Mol Biol Rep 39: 9095-9104, 2012.
23. Singh M, Goel S, Meeley RB, et al: Production of viable gametes without meiosis in maize deficient for an ARGONAUTE protein. Plant Cell 23: 443-458, 2011.
24. Soucek P, Susova S, Mohelnikova-Duchonova B, et al: Polymorphisms in metabolizing enzymes and the risk of head and neck squamous cell carcinoma in the Slavic population of the central Europe. Neoplasma 57: 415-421, 2010.
25. Mikami K, Naito M, Ishiguro T, et al: Immunological quantitation of DT-diaphorase in carcinoma cell lines and clinical colon cancers: advanced tumors express greater levels of DT-diaphorase. Jpn J Cancer Res 89: 910-915, 1998.
26. Fagerholm R, Sprott K, Heikkinen T, et al: Overabundant FANCD2, alone and combined with NQO1, is a sensitive marker of adverse prognosis in breast cancer. Ann Oncol 24: 2780-2785, 2013.
27. Li LS, Bey EA, Dong Y, et al: Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy. Clin Cancer Res 17: 275-285, 2011.
28. Vasiliou V, Ross D and Nebert DW: Update of the NAD(P) H:quinine oxidoreductase (NQO) gene family. Hum Genomics 2: 329-335, 2006.